| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
PCI Biotech Holding ASA (OL: PCIB)
PCIB Technical Analysis
5
| As on 21st Nov 2024 PCIB STOCK Price closed @ 1.40 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.93 & Strong Sell for SHORT-TERM with Stoploss of 2.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
PCIBSTOCK Price
| Open | 1.28 | Change | Price | % |
| High | 1.69 | 1 Day | 0.07 | 5.26 |
| Low | 1.28 | 1 Week | 0.12 | 9.38 |
| Close | 1.40 | 1 Month | -0.35 | -20.00 |
| Volume | 244425 | 1 Year | -1.43 | -50.53 |
| 52 Week High 2.90 | 52 Week Low 1.23 | ||||
OL Norway Most Active Stocks
| AOW | 2.00 | -5.21% |
| NEL | 2.92 | -5.19% |
| AKH | 1.78 | -13.17% |
| EAM | 0.16 | -5.88% |
| ASA | 0.08 | 0.00% |
| IDEX | 0.13 | 0.00% |
| MPCC | 25.80 | -3.01% |
| EQNR | 277.50 | 2.68% |
| NHY | 71.84 | 0.06% |
| NODL | 0.23 | -11.54% |
OL Norway Top Gainers Stocks
OL Norway Top Losers Stocks
| PCIB Daily Charts |
PCIB Intraday Charts |
Whats New @ Bazaartrend |
PCIB Free Analysis |
|
|
PCIB Important Levels Intraday
| RESISTANCE | 2.19 |
| RESISTANCE | 1.94 |
| RESISTANCE | 1.78 |
| RESISTANCE | 1.62 |
| SUPPORT | 1.18 |
| SUPPORT | 1.02 |
| SUPPORT | 0.86 |
| SUPPORT | 0.61 |
PCIB Forecast November 2024
| 4th UP Forecast | 2.27 |
| 3rd UP Forecast | 1.99 |
| 2nd UP Forecast | 1.82 |
| 1st UP Forecast | 1.65 |
| 1st DOWN Forecast | 1.15 |
| 2nd DOWN Forecast | 0.98 |
| 3rd DOWN Forecast | 0.81 |
| 4th DOWN Forecast | 0.53 |
PCIB Weekly Forecast
| 4th UP Forecast | 2.23 |
| 3rd UP Forecast | 1.96 |
| 2nd UP Forecast | 1.80 |
| 1st UP Forecast | 1.63 |
| 1st DOWN Forecast | 1.17 |
| 2nd DOWN Forecast | 1.00 |
| 3rd DOWN Forecast | 0.84 |
| 4th DOWN Forecast | 0.57 |
PCIB Forecast2024
| 4th UP Forecast | 6.02 |
| 3rd UP Forecast | 4.54 |
| 2nd UP Forecast | 3.62 |
| 1st UP Forecast | 2.71 |
| 1st DOWN Forecast | 0.09 |
| 2nd DOWN Forecast | -0.82 |
| 3rd DOWN Forecast | -1.74 |
| 4th DOWN Forecast | -3.22 |
PCI Biotech Holding ASA ( OL Norway Symbol : PCIB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
PCIB Business Profile
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's lead product candidate is Amphinex, a photosensitiser fimaporfin. Its PCI technology is applied to three distinct anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer, which in Phase Ib clinical study in bile duct cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination; and fimaNAc, a nucleic acid therapeutics delivery technology. The company has collaborative research programs with AstraZeneca, Bavarian Nordic, BioNTech, eTheRNA immunotherapies, IMV, Phio Pharmaceuticals, and OliX Pharmaceuticals Inc. PCI Biotech Holding ASA is headquartered in Oslo, Norway. Address: UllernchaussEen 64, Oslo, Norway, 0379
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service